MX2009007054A - Uso terapeutico novedoso para tratar leucemia. - Google Patents

Uso terapeutico novedoso para tratar leucemia.

Info

Publication number
MX2009007054A
MX2009007054A MX2009007054A MX2009007054A MX2009007054A MX 2009007054 A MX2009007054 A MX 2009007054A MX 2009007054 A MX2009007054 A MX 2009007054A MX 2009007054 A MX2009007054 A MX 2009007054A MX 2009007054 A MX2009007054 A MX 2009007054A
Authority
MX
Mexico
Prior art keywords
therapeutic use
novel therapeutic
treating leukaemia
leukaemia
treating
Prior art date
Application number
MX2009007054A
Other languages
English (en)
Inventor
Bernard Bourrie
Pierre Casellas
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38268928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009007054(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2009007054A publication Critical patent/MX2009007054A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a un uso terapéutico novedoso para tratar leucemia, en particular leucemia mieloide.
MX2009007054A 2006-12-28 2007-12-27 Uso terapeutico novedoso para tratar leucemia. MX2009007054A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0611492A FR2910813B1 (fr) 2006-12-28 2006-12-28 Nouvelle utilisation therapeutique pour le traitement des leucemies
PCT/FR2007/002171 WO2008102075A2 (fr) 2006-12-28 2007-12-27 Nouvelle utilisation therapeutique pour le traitement des leucemies

Publications (1)

Publication Number Publication Date
MX2009007054A true MX2009007054A (es) 2009-08-12

Family

ID=38268928

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007054A MX2009007054A (es) 2006-12-28 2007-12-27 Uso terapeutico novedoso para tratar leucemia.

Country Status (40)

Country Link
US (1) US8236811B2 (es)
EP (1) EP2107906B1 (es)
JP (1) JP5317987B2 (es)
KR (1) KR101458233B1 (es)
CN (1) CN101568338B (es)
AR (1) AR064550A1 (es)
AT (1) ATE534392T1 (es)
AU (1) AU2007347370B2 (es)
BR (1) BRPI0720963A2 (es)
CA (1) CA2672716C (es)
CL (1) CL2007003846A1 (es)
CO (1) CO6190610A2 (es)
CR (1) CR10881A (es)
CY (1) CY1112443T1 (es)
DK (1) DK2107906T3 (es)
EA (1) EA016873B1 (es)
EC (1) ECSP099449A (es)
ES (1) ES2377843T3 (es)
FR (1) FR2910813B1 (es)
GT (1) GT200900168A (es)
HK (1) HK1138189A1 (es)
HR (1) HRP20120170T1 (es)
JO (1) JO2748B1 (es)
MA (1) MA31100B1 (es)
MX (1) MX2009007054A (es)
MY (1) MY148515A (es)
NI (1) NI200900129A (es)
NO (1) NO20092496L (es)
NZ (1) NZ577991A (es)
PE (1) PE20081548A1 (es)
PL (1) PL2107906T3 (es)
PT (1) PT2107906E (es)
RS (1) RS52162B (es)
SI (1) SI2107906T1 (es)
SV (1) SV2009003315A (es)
TN (1) TN2009000234A1 (es)
TW (1) TWI433678B (es)
UA (1) UA97505C2 (es)
WO (1) WO2008102075A2 (es)
ZA (1) ZA200904478B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948568B1 (fr) * 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique
EP2638911A1 (en) 2012-03-14 2013-09-18 Sanofi Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia
EP3079667B1 (en) * 2013-12-13 2019-06-26 Novartis AG Pharmaceutical dosage forms
US20230136218A1 (en) * 2019-09-23 2023-05-04 President And Fellows Of Harvard College Methods and compositions for treating acute myeloid leukemia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) * 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
ES2146782T3 (es) 1994-11-14 2000-08-16 Warner Lambert Co 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa.
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
WO2001021577A2 (en) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
PL356802A1 (en) 2000-01-25 2004-07-12 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
WO2001070741A1 (en) 2000-03-06 2001-09-27 Warner-Lambert Company 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
BR0112857A (pt) 2000-08-04 2005-02-09 Warner Lambert Co Compostos 2-(4-piridil)amino-6-dialcoxifenil-pirido-[2,3-d]pirimidin- 7-onas
AU2002324450A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
US20050009849A1 (en) 2003-01-03 2005-01-13 Veach Darren R. Pyridopyrimidine kinase inhibitors
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
FR2873118B1 (fr) * 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
UY29017A1 (es) 2004-07-16 2006-02-24 Boehringer Ingelheim Int Inhibidores de polimerasa viral
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.

Also Published As

Publication number Publication date
US8236811B2 (en) 2012-08-07
AU2007347370A1 (en) 2008-08-28
KR20090103899A (ko) 2009-10-01
ECSP099449A (es) 2009-07-31
PE20081548A1 (es) 2009-01-04
WO2008102075A3 (fr) 2008-12-11
RS52162B (en) 2012-08-31
UA97505C2 (ru) 2012-02-27
CL2007003846A1 (es) 2009-01-23
SV2009003315A (es) 2010-02-05
AU2007347370B2 (en) 2013-05-23
DK2107906T3 (da) 2012-03-19
ATE534392T1 (de) 2011-12-15
HK1138189A1 (en) 2010-08-20
NO20092496L (no) 2009-07-23
EA016873B1 (ru) 2012-08-30
TWI433678B (zh) 2014-04-11
BRPI0720963A2 (pt) 2014-03-18
JO2748B1 (en) 2014-03-15
CR10881A (es) 2009-08-12
NI200900129A (es) 2011-12-13
PL2107906T3 (pl) 2012-04-30
ZA200904478B (en) 2010-08-25
EP2107906B1 (fr) 2011-11-23
PT2107906E (pt) 2012-03-05
TN2009000234A1 (fr) 2010-10-18
KR101458233B1 (ko) 2014-11-04
CN101568338B (zh) 2011-11-23
EP2107906A2 (fr) 2009-10-14
NZ577991A (en) 2012-01-12
GT200900168A (es) 2010-03-19
MA31100B1 (fr) 2010-01-04
SI2107906T1 (sl) 2012-03-30
MY148515A (en) 2013-04-30
EA200970639A1 (ru) 2010-04-30
AR064550A1 (es) 2009-04-08
TW200833343A (en) 2008-08-16
CA2672716A1 (fr) 2008-08-28
US20090298790A1 (en) 2009-12-03
JP5317987B2 (ja) 2013-10-16
ES2377843T3 (es) 2012-04-02
FR2910813B1 (fr) 2009-02-06
HRP20120170T1 (hr) 2012-03-31
JP2010514743A (ja) 2010-05-06
CY1112443T1 (el) 2015-12-09
CN101568338A (zh) 2009-10-28
WO2008102075A2 (fr) 2008-08-28
CO6190610A2 (es) 2010-08-19
FR2910813A1 (fr) 2008-07-04
CA2672716C (fr) 2013-05-28

Similar Documents

Publication Publication Date Title
TN2014000134A1 (en) Therapeutic peptides
MX2008001799A (es) Composicion farmaceutica que comprende un inhibidor de dipeptidil peptidasa iv.
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
TW200727908A (en) Herbal composition for treating cancer
MX2009003362A (es) Uso de interleucina-10 pegilada para tratamiento de cancer.
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
SI2043944T1 (sl) Obdelovalni stroj
PL1981826T5 (pl) Płyta budowlana
TW200744567A (en) Phenylethylamine analogs and their use for treating glaucoma
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
EA201000433A1 (ru) Лечение вазомоторных симптомов
MX2009007054A (es) Uso terapeutico novedoso para tratar leucemia.
JO2730B1 (en) Medications for the treatment of endometriosis
GB0607952D0 (en) Novel treatment
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
UA96476C2 (ru) Фармацевтические композиции, которые содержат ирбесартан
MX2009012096A (es) Axomadol para tratamiento de dolor con artritis.
TW200733962A (en) Novel crystalline form of vinflunine
ZA200705490B (en) Substituted benzimidazoles for treatment of histomoniasis
GB0523291D0 (en) Treatment table
MX2009006313A (es) Antagonistas v3 para el tratamiento o prevencion de dolor cronico.
AU312363S (en) Cross my heart dress
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer
CA118235S (en) Goalie leg pad
UA27272U (en) Use of yakton as cardioprotector

Legal Events

Date Code Title Description
FG Grant or registration